ADXS-HPV-Quad

N/A

Report date: 2025/03/14 16:50:31

Base Information

Drug NameADXS-HPV-Quad
Drug Alias NameListeria monocytogenes vector-based immunotherapy (Advaxis)
ClassificationBiologics > Protein drugs > Recombinant protein > Fusion protein
Mechanisms of ActionProtein E6 stimulantsProtein E7 stimulants
TargetsProtein E6Protein E7
Therapy Area/IndicationsUterine Cervical NeoplasmsHead and Neck NeoplasmsAnus Neoplasms +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesAyala Pharmaceuticals Inc
China Registration ClassN/A

Develop Information

Active CompaniesAyala Pharmaceuticals Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsHead and Neck NeoplasmsAnus Neoplasms +[4] 
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A